Bruce Altevogt, PhD, is a Director of Science Policy and Science Advocacy within Pfizer Inc.’s Global Policy and International Public Affairs. In this role, Dr. Altevogt is responsible for managing policy issues in support of Pfizer’s research & development enterprise. In addition, he is responsible for developing and implementing a science advocacy platform, which includes a public affairs and stakeholder management functions. Finally, he provides policy support for the Neuroscience and Pain, Vaccines, and Established Products business units. Prior to joining Pfizer Inc. Dr. Altevogt spent over 11 years as a senior program officer at the U.S. Institute of Medicine (IOM) leading policy initiatives related to basic and translational research, drug discovery and development, and preparedness for catastrophic events. Dr. Altevogt received his doctorate from Harvard University’s Program in Neuroscience and his B.A. from the University of Virginia in Charlottesville, where he majored in Biology and minored in South Asian Studies.
Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE (2014) Improving and accelerating drug development for nervous system disorders. Neuron 84 (3): 546-53.
Gostin LO, Altevogt BM, Pope AM (2014) Future oversight of recombinant DNA research: recommendations of an Institute of Medicine committee. JAMA 311 (7): 671-2.
Altevogt BM, Pankevich DE, Pope AM, Kahn JP (2012) Research agenda. Guiding limited use of chimpanzees in research. Science 335 (6064): 41-2.